Insmed To Present at the BofA Securities 2025 Health Care Conference

Rhea-AI Summary

Insmed (Nasdaq: INSM), a global biopharmaceutical company focused on developing first- and best-in-class therapies for serious diseases, has announced its upcoming presentation at the BofA Securities 2025 Health Care Conference.

The presentation is scheduled for Tuesday, May 13, 2025, at 2:20 p.m. PT in Las Vegas. Interested parties can access the live webcast through the investor relations section of Insmed's website at www.insmed.com.

Key Details:

• Event: BofA Securities 2025 Health Care Conference
• Location: Las Vegas
• Date & Time: May 13, 2025, 2:20 p.m. PT
• Webcast Duration: Archive available for 30 days post-event

Positive

• Management visibility through participation in a major healthcare conference
• Live webcast accessibility for 30 days enhances investor transparency

Negative

• None.

BRIDGEWATER, N.J., April 29, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the BofA Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025, at 2:20 p.m. PT.

This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more.

Contact:

Investors:

Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
investor.relations@insmed.com

Media:

Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
media@insmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-the-bofa-securities-2025-health-care-conference-302440428.html

SOURCE Insmed Incorporated

FAQ

When is Insmed (INSM) presenting at the BofA Securities 2025 Health Care Conference?

Insmed (INSM) will present at the BofA Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025, at 2:20 p.m. PT.

How can investors watch Insmed's (INSM) presentation at the BofA Securities conference?

Investors can watch the presentation live via webcast by visiting Insmed's investor relations section at www.insmed.com. The webcast will be archived for 30 days after the event.

Where is the BofA Securities 2025 Health Care Conference with Insmed (INSM) being held?

The BofA Securities 2025 Health Care Conference featuring Insmed's presentation will be held in Las Vegas.

How long will Insmed's (INSM) BofA Securities conference webcast be available?

The webcast of Insmed's presentation will be archived and available for 30 days following the live event.

What type of company is Insmed (INSM)?

Insmed is a people-first global biopharmaceutical company that develops first- and best-in-class therapies for patients with serious diseases.